Cantor Fitzgerald reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC). The biotech firm has a market cap of $875.76 million, delivering a 42% return over the past year.
Key opinion leaders assign a 60% probability of success to Pfizer's MEVPRO-1 trial, which has implications for ORIC.
ORIC holds more cash than debt, providing financial flexibility as it awaits trial results.
Goldman Sachs upgraded ORIC to Buy with a $15.00 target, citing rinzimetostat's potential peak sales of $2.6 billion.
H.C. Wainwright reiterated Buy with a $25.00 target, while Wolfe Research maintained Peerperform.
